Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for GH Research PLC (GHRS : NSDQ)

• Company Description    GH Research PLC is a clinical-stage biopharmaceutical company. It dedicated to treat psychiatric and neurological disorders. The company's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. GH Research PLC is based in DUBLIN. Number of Employees: 73

• Price / Volume Information    Yesterday's Closing Price: $22.12 Daily Weekly Monthly 20 Day Moving Average: 213,905 shares Shares Outstanding: 68.61 (millions) Market Capitalization: $1,517.63 (millions) Beta: 1.27 52 Week High: $24.66 52 Week Low: $10.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.60% 11.85% 12 Week 41.52% 30.83% Year To Date 74.17% 57.60%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL JOSHUA DAWSON HOUSE DAWSON STREET - DUBLIN,L2 D02 RY95 IRL ph: 353-1437-8334 fax: - investors@ghres.com http://www.ghres.com

• General Corporate Information    Officers Velichka Valcheva - Chief Executive Officer Florian Schonharting - Chairman Michael Forer - Vice Chairman Dermot Hanley - Director Duncan Moore - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G3855L106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 68.61 Most Recent Split Date: (:1) Beta: 1.27 Market Capitalization: $1,517.63 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.46 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.91 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -63.16% vs. Previous Quarter: -34.78% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -19.36 12/31/25 - -16.30 09/30/25 - -15.84 ROA 03/31/26 - -18.73 12/31/25 - -15.77 09/30/25 - -15.27 Current Ratio 03/31/26 - - 12/31/25 - 34.13 09/30/25 - 28.32 Quick Ratio 03/31/26 - - 12/31/25 - 34.13 09/30/25 - 28.32 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - - 12/31/25 - 4.51 09/30/25 - 5.60 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - 0.05 09/30/25 - 0.07

Powered by Zacks Investment Research ©